VEGFA and neoplasm: TRC105, also known as carotuximab, (TRACON Pharmaceuticals, Inc., San Diego, CA, USA) is a chimeric IgG1 antibody that binds human endoglin with high avidity, induces antibody-dependent cellular cytotoxicity (ADCC) and apoptosis of human vascular endothelial cells (HUVECs) and endoglin-positive tumor cells, and inhibits angiogenesis in response to VEGF and fibroblast growth factor.